Updated August 3, 2026

Farxiga Patient Assistance 2026: Copay Assistance, Phone Number & What Changed

Evan Brown
Written by Evan Brown
Prescription Savings Researcher
Dr Megan Harris Medically Reviewed by Dr. Megan Harris, MD
Medical Review: This guide covers AstraZeneca's AZ&Me Patient Assistance Program for Farxiga (dapagliflozin), the May 2026 change that closed it to new applicants, who remains covered, and current alternatives including the Farxiga savings card and generic dapagliflozin.
Quick Answer

AstraZeneca's AZ&Me program closed to new Farxiga applicants on May 1, 2026. Already enrolled patients receive free medication through December 31, 2026. For new patients, the Farxiga Savings Card reduces costs to as low as $0/month for commercially insured patients (max savings $175 per 30-day supply). Cash-paying patients save up to $150 per fill. The official list price is $377.82 for a 30-day supply. Medicare Part D beneficiaries pay a maximum of $179/month under the IRA negotiated price, with an annual out-of-pocket cap of $2,100. Generic dapagliflozin — FDA-approved in April 2026 — now costs approximately $21-$80/month with a discount card, making it the cheapest option for most uninsured patients.

Key Takeaways

  • New Farxiga/Xigduo XR applicants have not been accepted into AZ&Me since May 1, 2026.
  • Patients enrolled before that date keep receiving assistance only through December 31, 2026.
  • The stated reason is the broad rollout of generic dapagliflozin during 2026.
  • The separate Farxiga Savings Card still exists but excludes anyone with government insurance.
  • Generic dapagliflozin, not a free-drug program, is now the primary affordability path for most new patients.

Farxiga Cost Without Insurance 2026

Without insurance or patient assistance, Farxiga's official list price is $377.82 for a 30-day supply as of January 1, 2026. However, pharmacies often charge more at retail cash price.

Farxiga cost without insurance (July 2026)
Price Type 30-Day Supply (10 mg) Source
Manufacturer list price $377.82 AstraZeneca, Jan 2026
Typical retail cash price $550–$650 Pharmacy retail
GoodRx coupon price ~$288–$375 GoodRx (varies by pharmacy)
SingleCare coupon price ~$374–$453 SingleCare
Costco/Sam's Club cash ~$330–$380 Warehouse pharmacies

Bottom line: Never pay the full retail cash price. Even without insurance, a free discount card or warehouse pharmacy membership can cut your cost by 30–50%.

Looking for a Farxiga coupon? There is no printable manufacturer coupon. The Farxiga Savings Card functions as a coupon — it reduces your cost to as low as $0/month (commercially insured, max $175 savings) or list price minus $150 (cash-paying). Enroll at MyFarxiga.com or call 1-844-631-3978. For the lowest uninsured price, ask your doctor about generic dapagliflozin (~$21–$80/month with a discount card).

Farxiga Assistance Options at a Glance (2026)

Option Who Qualifies Your Cost Max Savings How to Apply
Farxiga Savings Card (commercially insured) Commercial insurance that covers Farxiga As low as $0/month $175 per 30-day supply MyFarxiga.com or 1-844-631-3978
Farxiga Savings Card (cash-paying) Uninsured, paying cash List price minus $150 $150 per monthly prescription MyFarxiga.com or 1-844-631-3978
Generic Dapagliflozin Anyone with a prescription ~$21–$80 with discount card No limit Ask prescriber to switch
AZ&Me PAP CLOSED to new applicants as of May 1, 2026 N/A N/A No longer accepting applications
Medicare Part D Medicare beneficiaries Max $179/month (IRA negotiated) $2,100 annual OOP cap Automatic through Part D plan

Bottom line: The free manufacturer PAP is closed to new patients, but the Farxiga Savings Card and generic dapagliflozin are active, realistic alternatives. Medicare patients should also check Extra Help (LIS) for Part D support.

Search "Farxiga patient assistance program" today and you'll find a wall of pages describing AZ&Me as if you can still sign up for free brand-name Farxiga. As of mid-2026, that's out of date for anyone applying for the first time — and publishing that information without the update risks sending someone down a dead-end application process.

Here's what actually happened, who it affects, and what a realistic plan looks like now depending on whether you're already enrolled, brand new to Farxiga, or somewhere in between.

Farxiga (dapagliflozin) treats type 2 diabetes, heart failure and chronic kidney disease, and its uninsured cash price has generally run in the $550–$780 range for a 30-day supply depending on pharmacy and region. That price is exactly why the assistance program mattered so much — and exactly why its closure to new patients is worth understanding in detail before you build a plan around it.

Table of Contents

  1. What Changed on May 1, 2026
  2. Are You Affected? Three Scenarios
  3. Farxiga Savings Card vs AZ&Me vs Generic: Comparison
  4. Copay Assistance & Phone Numbers
  5. Patient Portal & Card Download
  6. Does Medicaid Cover Farxiga?
  7. Decision Tree: What's Your Move?
  8. Step-by-Step: Switching to Generic Dapagliflozin
  9. What to Do If You're Denied or Priced Out
  10. Frequently Asked Questions

What Changed on May 1, 2026

AstraZeneca's AZ&Me Prescription Savings Program — the charitable arm that had provided free Farxiga to qualifying uninsured and underinsured patients — stopped taking new Farxiga and Xigduo XR applications on that date. AstraZeneca notified currently enrolled patients and their providers about the change the month before, in April 2026.

Date Event
April 2026 AstraZeneca notifies enrolled patients and providers of the upcoming change
May 1, 2026 AZ&Me stops accepting new Farxiga and Xigduo XR applicants
May 1 – Dec 31, 2026 Already-enrolled patients continue receiving assistance
December 31, 2026 AZ&Me support for Farxiga and Xigduo XR ends entirely

Why this happened: AstraZeneca's stated reasoning is the arrival of generic dapagliflozin in broad supply during 2026. Manufacturer patient assistance programs generally exist to bridge the gap for brand-name drugs without an affordable generic — once that gap closes, the manufacturer typically winds the program down for that specific drug rather than keeping it open indefinitely.

Are You Affected? Three Scenarios

Your Situation What This Means for You
Enrolled in AZ&Me for Farxiga before May 1, 2026 Assistance continues through December 31, 2026 — plan your next step before then
Newly prescribed Farxiga after May 1, 2026, uninsured or underinsured AZ&Me is not an option — look at generic dapagliflozin or independent foundations instead
Commercially insured, any date AZ&Me was never your program — the Farxiga Savings Card is the relevant tool, unaffected by this change

Farxiga Savings Card vs AZ&Me vs Generic Dapagliflozin

These three options solve different problems, and only one of them — the savings card — is unaffected by the May 2026 closure.

Feature Farxiga Savings Card AZ&Me (Farxiga) Generic Dapagliflozin
Current status Active, unaffected Closed to new applicants since May 2026 Available, growing pharmacy stock through 2026
Who it's for Commercially insured or cash-paying patients Previously: uninsured/underinsured, income-qualifying Anyone with a prescription for dapagliflozin
Cost to patient As low as $0, up to $175 savings per 30-day fill $0 for those still enrolled through Dec 31, 2026 ~$21–$80 with a discount card (85–95% savings vs. brand)
Medicare/Medicaid eligible? No Previously yes, case-by-case Yes, if your Part D or Medicaid formulary covers the generic
Income requirement None Previously ≤300% FPL for this drug category None

The practical shift: Before May 2026, the path for an uninsured patient was "apply to AZ&Me and get brand Farxiga free." Now, for a new patient, the realistic path is "ask your prescriber about generic dapagliflozin, then use a pharmacy discount card to get the generic price down further." That's a real change in the cost math, not just a paperwork inconvenience.

How to Apply for the Farxiga Savings Card in 2026

The Farxiga Savings Card is unaffected by the AZ&Me closure and remains the fastest way to lower your out-of-pocket cost for brand-name Farxiga.

1

Confirm your insurance type

You must have commercial insurance or be paying cash. Medicare, Medicaid, TRICARE, VA, and other government-funded plans make you ineligible.

2

Register online or by phone

Visit MyFarxiga.com or call the Farxiga support line. You'll need your insurance card and prescription details.

3

Present the card at the pharmacy

Most pharmacies can process the savings card immediately. If your pharmacy hasn't seen it before, ask them to process it as a manufacturer copay card.

Maximum savings (commercially insured): The card covers up to $175 per 30-day supply. If your copay is higher, you pay the difference. If lower, you may pay $0.

Cash-paying patients: AstraZeneca pays the first $150 of your prescription. You pay the remaining balance.

Phone: 1-844-631-3978 or 1-800-236-9933. Online: MyFarxiga.com

Restrictions: Must be 18+, US or Puerto Rico resident. Not for Medicare, Medicaid, TRICARE, VA, DOD, or other government programs.

Farxiga Copay Assistance & Phone Numbers

Patients searching for Farxiga copay assistance or the manufacturer phone number need direct, scannable contact info. As of August 2026, AstraZeneca handles Farxiga support through two main lines and the MyFarxiga patient portal.

Official Farxiga manufacturer phone numbers (August 2026)
Purpose Phone Number Hours (ET)
Farxiga Savings Card & Copay Assistance 1-844-631-3978 Mon–Fri, 8am–8pm
Farxiga General Support 1-800-236-9933 Mon–Fri, 8am–8pm
Patient Portal (MyFarxiga) MyFarxiga.com — register, download card, check savings status

What to say when you call: "I need to enroll in the Farxiga Savings Card" or "My pharmacy can't process my Farxiga copay card." Have your insurance card and prescription details ready. The savings card is not the same as the AZ&Me patient assistance program, which is closed to new Farxiga applicants.

Farxiga Patient Portal: MyFarxiga.com Login & Card Download

The MyFarxiga patient portal is where you register for the savings card, download a printable or digital card, and check your remaining savings balance.

1

Register at MyFarxiga.com

Visit MyFarxiga.com and create an account with your name, email, and insurance information.

2

Download or print your savings card

Once registered, you can download the Farxiga Savings Card as a PDF to print, or save the digital version to your phone. Most pharmacies can scan the digital barcode directly from your screen.

3

Check savings status and refill reminders

The portal tracks how much of your annual savings benefit you've used and can send refill reminders.

MyFarxiga is not the same as AZ&Me. The patient portal only handles the savings card (copay assistance). It does not process patient assistance program applications — AZ&Me closed to new Farxiga applicants on May 1, 2026.

If You're Already Enrolled in AZ&Me

1

Confirm your enrollment end date

Your assistance runs through December 31, 2026. Mark that date now rather than discovering it at the pharmacy counter in January 2027.

2

Talk to your prescriber about generic dapagliflozin before your enrollment ends

Switching before the cutoff, rather than after, avoids a gap month where you have neither active AZ&Me coverage nor an established generic prescription and pharmacy routine.

3

Check your specific insurance status for 2027

If your insurance situation has changed since you first enrolled, re-verify what coverage — commercial, Medicare, Medicaid, or none — you'll actually have once AZ&Me ends, since that determines which of the remaining options applies to you.

If You're New to Farxiga in 2026

1

Ask directly whether generic dapagliflozin fits your case

Generic dapagliflozin covers the same core FDA-approved uses as brand Farxiga for many patients. Ask your prescriber whether there's a clinical reason you specifically need the brand, since for most patients there isn't one.

2

If you have commercial insurance, use the Farxiga Savings Card only if you're prescribed the brand

The savings card applies to brand Farxiga specifically. If your plan already covers generic dapagliflozin at a lower copay, the card may not be relevant to your situation at all.

3

If you're uninsured, price-compare generic dapagliflozin across pharmacies

Cash prices for the generic have varied meaningfully by pharmacy and by discount card. Comparing a couple of nearby pharmacies plus a free discount card app before filling can meaningfully change your monthly cost.

4

If cost is still unmanageable, look at independent copay foundations

Nonprofit foundations that operate separately from AstraZeneca sometimes fund diabetes, heart failure or kidney disease medications and aren't affected by AZ&Me's Farxiga-specific closure.

Medicare and Medicaid Patients: Exact 2026 Costs

Medicare and Medicaid patients were never eligible for the Farxiga Savings Card, and the AZ&Me closure removes what had been one of the only manufacturer-side options for brand-name Farxiga. However, two major 2026 changes reduce Medicare costs significantly:

Coverage Detail Cost
IRA negotiated price (maximum) $179 per 30-day supply
Annual out-of-pocket cap $2,100 (then $0 for rest of year)
Average Medicare Part D copay ~$38.82/month
2026 Part D deductible ~$615 (must be met first)
With Extra Help (LIS) $0–$15/month

How the $2,100 cap works: Once your total out-of-pocket spending on all Part D drugs reaches $2,100 in 2026, your Farxiga copay drops to $0 for the rest of the year. If you only take Farxiga at $179/month, you may not hit the cap — but the negotiated price still saves you hundreds vs. retail.

Coverage Brand Farxiga Generic Dapagliflozin
Medicare Part D Covered, often Tier 3; max $179 under IRA Usually Tier 1–2 (lower copay) once on formulary
Medicaid Varies by state; may require PA Generally preferred; lower cost
Farxiga Savings Card Not eligible Not applicable

For low-income Medicare patients: If your Part D copay is still unaffordable, apply for Extra Help (Low-Income Subsidy) through the Social Security Administration. It can reduce premiums, deductibles, and copays to near $0.

Does Medicaid Cover Farxiga?

Yes — Medicaid covers generic dapagliflozin in most states as of August 2026, typically as a preferred formulary drug with minimal or no copay. Brand Farxiga coverage varies by state and may require prior authorization (PA) proving medical necessity.

Medicaid coverage for Farxiga vs. generic dapagliflozin (August 2026)
Coverage Type Brand Farxiga Generic Dapagliflozin
Medicaid Varies by state; PA often required Usually preferred; $0–$3 copay
Medicare Part D Covered; max $179/month under IRA Usually Tier 1–2; lower copay
Farxiga Savings Card Not eligible Not applicable

Medicaid patients: Ask your pharmacist to fill generic dapagliflozin rather than brand Farxiga. Most state Medicaid formularies added the generic in Q2 2026 after the April FDA approval. If your state still requires PA for the generic, your prescriber can submit a formulary exception request.

Important: The Farxiga Savings Card (copay assistance) is not available to Medicaid beneficiaries. If you have Medicaid, your path is generic dapagliflozin through your state formulary — not the manufacturer savings card.

Decision Tree: What's Your Move?

Were you enrolled in AZ&Me for Farxiga before May 1, 2026?

This single date determines your path

Yes, Already Enrolled

Coverage continues to Dec 31, 2026

Use this time to plan your next step

Switch to generic before the cutoff

Avoid a coverage gap in January

No, New to Farxiga

Have commercial insurance?

Determines whether savings card applies

Ask about generic dapagliflozin first

Then layer a savings card or discount program on top

Still unaffordable?

Independent copay foundations are your remaining option

Step-by-Step: Switching to Generic Dapagliflozin

1

Bring it up at your next appointment, or call in between

Ask specifically: "Is there a clinical reason I need brand Farxiga instead of generic dapagliflozin?" For most patients, the answer is no, and the switch is straightforward.

2

Confirm your pharmacy has the generic in stock

Generic availability expanded through 2026 but supply has varied by pharmacy and region during the rollout. Call ahead before showing up expecting an immediate fill.

3

Compare cash price with a discount card even if you have insurance

Occasionally a discount card's generic price beats your plan's copay, particularly on high-deductible plans early in the year. It costs nothing to compare both at the counter.

4

Watch your first few fills for any difference in effect

Generic dapagliflozin uses the same active ingredient as brand Farxiga. If you notice any unexpected changes after switching, that's worth a call to your prescriber, though it isn't expected with a straightforward generic substitution.

Generic Dapagliflozin Prices by Pharmacy (July 2026)

Since the FDA approved generic dapagliflozin on April 6, 2026, prices have fallen significantly. Here are current cash prices with discount cards:

Generic dapagliflozin 10 mg, 30 tablets — discount card prices
Pharmacy Approximate Price Savings vs. Brand
Costco / Sam's Club ~$21–$35 ~90–95%
Walmart ~$25–$45 ~88–93%
CVS Pharmacy ~$30–$55 ~85–92%
Walgreens ~$35–$60 ~84–90%
Kroger ~$28–$50 ~87–92%
Independent pharmacies ~$40–$80 ~78–89%

Important: Generic dapagliflozin was approved in April 2026 and availability is still expanding. Not all pharmacies stock it yet — call ahead. If your pharmacy doesn't have it, ask them to order it or try a different location.

What to Do If You're Denied or Priced Out

1. Don't assume "no PAP" means "no help." The manufacturer program closing to new Farxiga patients doesn't eliminate every assistance option — it removes one specific one.

2. Check independent copay and disease-specific foundations. Organizations such as the PAN Foundation, the HealthWell Foundation and NeedyMeds operate separately from AstraZeneca and periodically fund diabetes, heart failure and chronic kidney disease medications.

3. Ask your pharmacist about the lowest verified cash price nearby. Generic pricing has varied enough between pharmacies that a quick call-around can be worth real money.

4. Revisit Extra Help if you're on Medicare. Low-income Medicare beneficiaries who haven't applied for the Part D Low-Income Subsidy may be leaving real savings on the table on both brand and generic dapagliflozin copays.


Frequently Asked Questions

No. AstraZeneca's AZ&Me program stopped accepting new Farxiga and Xigduo XR applicants as of May 1, 2026, because generic dapagliflozin became broadly available.

Patients who were already enrolled before May 1, 2026 continue receiving assistance through December 31, 2026, after which the program ends for this medication.

AstraZeneca cited the broad availability of generic dapagliflozin as the reason, since patient assistance programs are generally intended for brand-name drugs without an affordable generic alternative.

No. The Farxiga Savings Card is only available to commercially insured or cash-paying patients. Medicare, Medicaid, TRICARE and other government-funded insurance make you ineligible for the manufacturer copay card.

Ask your prescriber about switching to generic dapagliflozin, compare pharmacy discount card pricing, and look into independent copay foundations, since the manufacturer PAP is no longer accepting new Farxiga applicants.

Since AZ&Me closed to new uninsured applicants in May 2026, your best paths are: (1) ask your prescriber to switch you to generic dapagliflozin, which costs significantly less; (2) apply to an independent copay foundation like the PAN Foundation or HealthWell Foundation if you have a qualifying diagnosis; or (3) check whether you qualify for Medicare Extra Help if you're 65+.

The official list price is $377.82 for a 30-day supply. However, retail pharmacies typically charge $550–$650 cash. With a free discount card (GoodRx, SingleCare), brand Farxiga costs approximately $288–$453. The cheapest option is generic dapagliflozin, FDA-approved in April 2026, which costs $21–$80/month with a discount card.

Under the Inflation Reduction Act, Medicare Part D plans cannot be charged more than $179 per month for Farxiga in 2026. The average Medicare beneficiary pays approximately $38.82/month. Once your total annual out-of-pocket drug spending reaches $2,100, your Farxiga cost drops to $0 for the rest of the year.

The manufacturer PAP (AZ&Me) previously covered Medicare patients on a case-by-case basis, but new Medicare applicants are no longer accepted as of May 1, 2026. Medicare patients should instead look at generic dapagliflozin (often covered at a lower Part D tier) or apply for the Extra Help (LIS) program through Social Security to reduce Part D copays.

No. The Farxiga Savings Card is a copay card for commercially insured or cash-paying patients — it reduces your pharmacy cost but does not make the medication free. The AZ&Me Patient Assistance Program previously provided free medication to uninsured, income-qualified patients. That free-drug program is now closed to new Farxiga applicants.

Brand Farxiga's cash price typically runs $550–$780 for a 30-day supply. Generic dapagliflozin, with a pharmacy discount card, generally ranges from $30–$80 for the same supply — a reduction of roughly 85–90%. Prices vary by pharmacy and region, so comparing two or three locations is worthwhile.

Generic dapagliflozin contains the same active ingredient and is held to the same FDA bioequivalence standards as the brand version. Ask your prescriber if you have questions specific to your situation.

This specific closure applies to Farxiga and Xigduo XR. AstraZeneca has made separate, unrelated changes to other products in its portfolio at different times, so check the current AZ&Me program page for the status of any other medication.

Cash prices have varied, generally running somewhat below brand Farxiga's cash price and further reduced with a pharmacy discount card. Prices vary by pharmacy and region, so comparing a few options is worth the extra few minutes.

Not automatically. Prior authorizations are often tied to the specific drug and NDC submitted. Ask your pharmacy or insurer whether a new authorization is needed when switching from brand to generic.

No. This is a program-wide policy change affecting all new Farxiga applicants, not an individual eligibility denial, so there isn't an appeal process that reopens enrollment for this specific medication.


Yes. Most state Medicaid programs cover generic dapagliflozin as a preferred drug with little or no copay as of August 2026. Brand Farxiga may require prior authorization. The Farxiga Savings Card cannot be used with Medicaid.

The Farxiga Savings Card and copay assistance line is 1-844-631-3978 (Mon–Fri, 8am–8pm ET). General Farxiga support is available at 1-800-236-9933.

No — for new patients. AstraZeneca's AZ&Me program stopped accepting new Farxiga applications on May 1, 2026. There is no 2026 application form for new enrollees. If you were already enrolled before May 1, 2026, your coverage continues through December 31, 2026 with no new form required.

Farxiga copay assistance is the Farxiga Savings Card, a manufacturer copay card that reduces your pharmacy cost to as low as $0/month for commercially insured patients (max savings $175 per 30-day supply) or list price minus $150 for cash-paying patients. It is not a free-drug program — it is a discount applied at the pharmacy counter. Medicare, Medicaid, and TRICARE patients are ineligible.

Go to MyFarxiga.com and click "Sign In" or "Register." The portal lets you download your savings card, check your benefit balance, and set refill reminders. If you forgot your password, use the reset link on the login page or call 1-844-631-3978.

AstraZeneca does not offer a standalone "free 30-day trial" coupon for Farxiga as of August 2026. The Farxiga Savings Card is the active manufacturer discount program. Some prescribers may have starter vouchers, but these are limited and not guaranteed. For the lowest first-fill cost, ask about generic dapagliflozin (~$21–$80 with a discount card).

No. Manufacturer copay cards and coupons for Farxiga are federally prohibited for Medicare, Medicaid, TRICARE, VA, and DOD beneficiaries. Medicare patients should instead use generic dapagliflozin (often a lower Part D tier) or apply for Extra Help (LIS) to reduce copays.

Yes. The AZ&Me closure applies to both Farxiga (dapagliflozin) and Xigduo XR (dapagliflozin/metformin extended-release). New applicants for either medication are not accepted as of May 1, 2026. Already-enrolled patients for both drugs continue receiving assistance through December 31, 2026.

No. Manufacturer copay cards and coupons expire annually. A 2025 Farxiga coupon or savings card will be rejected at the pharmacy. You must enroll in the 2026 Farxiga Savings Card at MyFarxiga.com or by calling 1-844-631-3978 to receive current discounts.

How We Researched This Guide

This guide was prepared by the Refill Relay Editorial Team using AstraZeneca's own AZ&Me program update notices, the official Farxiga savings and support page, and current 2026 reporting on generic dapagliflozin availability and pricing. Where cash-price figures varied across sources, we presented a range rather than a single unverified number.


References

  1. AZ&Me — Important Program Updates (Farxiga/Xigduo XR closure notice)
  2. Farxiga.com — Savings and Insurance Support
  3. Social Security Administration — Extra Help with Medicare Prescription Drug Costs
  4. NeedyMeds — independent patient assistance directory
  5. HealthWell Foundation — independent copay assistance
  6. Patient Access Network (PAN) Foundation

About Refill Relay

Refill Relay publishes evidence-based educational resources that help patients understand prescription insurance, patient assistance programs, prior authorization requirements and medication access. Our editorial team tracks manufacturer program changes closely, since assistance programs can open, close or change eligibility with little public notice.

Editorial Standards

  • Sourced from manufacturer program update notices, not just legacy program descriptions
  • Clinical review before publication
  • Updated promptly when a program's eligibility or availability changes
  • Clear distinction between educational content and medical or financial advice

Related Resources

Editorial Policy: Refill Relay medical content is researched using manufacturer program pages and current pricing/availability reporting. Because this program's status changed mid-year and generic rollout and pricing continue to shift through 2026, always confirm current availability directly with AstraZeneca, your pharmacy, or your prescriber before making a decision.

Evan Brown
About the Author
Evan Brown — Prescription Savings Researcher

Evan Brown is a prescription savings researcher who specializes in translating complex healthcare policy — including manufacturer assistance program changes — into clear, actionable guidance for patients.

View Full Profile →
Dr. Megan Harris, MD
Medical Review
Dr. Megan Harris, MD — Board-Certified Internal Medicine

Dr. Megan Harris, MD reviews health content for medical accuracy, checking clinical eligibility criteria and drug information against current manufacturer and CMS guidance.

View Full Profile →

Get Started with Refill Relay